SharadKumarJainMD

Oncology • Denton, TX

Physician

Join to view full profile

Dr. Jain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jain's full profile

Already have an account?

Office
3720 S I-35 E
Denton, TX 76210
Phone+1 940-382-1022

Fax+1 940-380-7904

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 1990 - 1992
University at BuffaloResidency, Internal Medicine, 1989 - 1990
Maulana Azad Medical CollegeClass of 1981

Certifications & Licensure

AZ State Medical License 1995 - Present
TX State Medical License 2001 - 2026
PA State Medical License 1991 - 1998
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
Completed
Phase 3
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

97 citations
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor
The Lancet. Oncology. 2021-07-01
1 citations
Rosai-Dorfman disease in a symptomatic elderly man
Gaurav Synghal, Risha Bhavan, Sharad Jain, Umesh Oza
Proceedings. 2021-08-12